Final answer:
Ninlaro (ixazomib) is the only medication listed that is not a Celgene product requiring enrollment in a REMS program. The other medications are Celgene products with associated REMS programs.
Step-by-step explanation:
The medication that is NOT a Celgene product requiring a patient to be enrolled in the manufacturer's REMS (Risk Evaluation and Mitigation Strategy) program is Ninlaro (ixazomib). The other medications listed, Thalomid (thalidomide), Pomalyst (pomalidomide), and Revlimid (lenalidomide), are all Celgene products associated with REMS programs due to their potential risks. REMS programs are designed to ensure that the benefits of these medications outweigh their risks.
It is important to know that the list given in the reference information, including methotrexate (Abitrexate®), fluorouracil (Adrucil®), hydroxyurea (Hydrea®), mercaptopurine (Purinethol®), and thioguanine, are different medications and are not the ones being asked about in this question.